Otsuka Pharmaceutical Europe has received an amended European Commission marketing [...]

BridgeBio has published results from its pivotal Phase 3 Propel [...]

Thalia Therapeutics has agreed a Sanmirna acquisition and £2.75m fundraise [...]

Absci has reported positive interim Phase 1 data for ABS-201, [...]

Inaqovi in combination with venetoclax has received an amended European [...]

Atsena Therapeutics has dosed the first patient in the Phase [...]

Spot Biosystems has emerged from stealth with $40 million in [...]

Gesynta Pharma has randomised half of the planned patients in [...]

spliesense-cystic-fibrosis-foundation-spl84-phase2b SpliSense has secured up to $13 million in funding [...]

The National Institute for Health and Care Excellence has recommended [...]